Professor Dave Singh: key facts
- Kind of voice
- Academic
- Role
- Pulmonologist and Clinical Pharmacologist, University of Manchester and Medicines Evaluation Unit, UK
- Quoted on
- Respiratory (asthma/COPD)
- Tracked press citations
- 2
- Most recently quoted
- 30 Sept 2026
- First quoted
- 10 Sept 2026
“described how the reduced (IL-33RED) and oxidised (IL-33OX) forms of IL-33 act through distinct pathways to promote inflammation, mucus dysfunction, and impaired epithelial repair in COPD”
What Professor Dave Singh has said
“the approval of the inhalers 'represents a significant step forward in sustainable respiratory care'. He said the evidence shows they work in the same way, so patients can maintain access to the treatment that works for them while the carbon footprint of these pMDIs is addressed in the background.”
professor of clinical pharmacology and respiratory medicine at the University of Manchester · Respiratory (asthma/COPD) · 10 Sept 2026 · UK regulator approves first lower-carbon asthma inhaler ↗
Where Professor Dave Singh has been quoted
- IL-33 Is Not Just IL-33: There Is More Than One Side to the COPD Storyemjreviews.com · 30 Sept 2026
- UK regulator approves first lower-carbon asthma inhalerpulsetoday.co.uk · 10 Sept 2026
Related media coverage
Recent UK press coverage of their topics — not necessarily citing them directly.
Professors, researchers and think-tank analysts quoted on the strength of their research rather than a clinical role. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. This profile was last updated on 5 Oct 2026. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.